Ticker
ABUS

Price
2.31
Stock movement down
-0.01 (-0.43%)
Company name
Arbutus Biopharma Corp
Exchange
(NASDAQ
,
Currency
USD
)
Sector
Healthcare >
Biotechnology
Markedsverdi
343.56M
Ent verdi
333.26M
Pris/omsetning
16.01
Pris/bok
-
Utbytte avkastning
-
Utbytte vekst
-
Vekst år
-
FCF-utbetaling
0.10%
Etterfølgende P/E
-
Fremtidig P/E
-
PEG
-
EPS-vekst
-
1 års avkastning
-29.14%
3 års avkastning
19.31%
5 års avkastning
-8.99%
10 års avkastning
-4.26%
Sist oppdatert: 2022-08-25

UTBYTTE

ABUS betaler ikke utbytte

VERDSETTELSE

Verdsettelsesforhold

Loading...
Verdsettelsesforhold-data
Etterfølgende P/E-
Pris til OCF0.02
Pris til FCF0.02
Pris til EBITDA-
EV i forhold til EBITDA-

Verdsettelse (Salg/Bokført verdi)

Loading...
Verdsettelse (Salg/Bokført verdi) data
Pris til omsetning16.01
Pris til bok-
EV i forhold til salg15.53

ØKONOMI

Per aksje

Loading...
Per aksje-data
Gjeldende aksje antall148.73M
EPS (TTM)-0.75
FCF per aksje (TTM)203.07

Resultatregnskap

Loading...
Resultatregnskap-data
Inntekter (TTM)21.46M
Bruttofortjeneste (TTM)8.88M
Driftsinntekter (TTM)-68.82M
Netto inntekt (TTM)-75.63M
EPS (TTM)-0.75
EPS (1 år fremover)-0.62

Marginer

Loading...
Marginer-data
Bruttomargin (TTM)41.36%
Driftsmargin (TTM)-320.75%
Fortjenestemargin (TTM)-352.49%

Balanse

Loading...
Opprett en gratis konto eller logg inn for å få tilgang til dette diagrammet
Balanse-data
Kontanter81.33M
Netto fordringer1.31M
Samlede omløpsmidler172.70M
Goodwill0.00
Immaterielle eiendeler0.00
Eiendom, anlegg og utstyr0.00
Sum eiendeler236.88M
Leverandørgjeld1.19M
Kortsiktig/nåværende langsiktig gjeld2.54M
Sum kortsiktig gjeld32.41M
Sum gjeld71.03M
Aksjonærenes egenkapital0.00
Netto varige driftsmidler165.84M

Kontantstrøm

Loading...
Opprett en gratis konto eller logg inn for å få tilgang til dette diagrammet
Kontantstrøm-data
Kontantstrøm fra drift (TTM)20.57B
Kapitalutgifter (TTM)710.00K
Fri kontantstrøm (TTM)20.57B
Utbetalt utbytte (TTM)20.44M

Finansielle inntekter

Loading...
Opprett en gratis konto eller logg inn for å få tilgang til dette diagrammet
Finansielle inntekter-data
Egenkapitalavkastning-
Avkastning på eiendeler-
Avkastning på investert kapital-
Kontantavkastning på investert kapital-

AKSJEINFORMASJON

Aksjediagram

Loading...
Aksjekurs-data
Åpning2.32
Daglig høy2.40
Daglig lav2.27
Daglig volum410K
Tidenes høyeste30.94
1 år analytikerestimat6.50
Beta2.44
EPS (TTM)-0.75
Utbytte per aksje-
Ex-div dato-
Neste dato for resultatpresentasjon2 Nov 2022

Nedsidepotensial

Loading...
Nedsidepotensial-data
ABUSS&P500
Nåværende prisfall fra toppnotering-92.53%-12.18%
Høyeste prisfall-97.19%-56.47%
Dato for høyeste fall9 Oct 20199 Mar 2009
Gj.snittlig fall fra topp-70.87%-11.38%
Gj.snittlig tid til ny topp110 days12 days
Maks tid til ny topp2132 days1805 days
SELSKAPSOPPLYSNINGER
ABUS (Arbutus Biopharma Corp) company logo
Markedsverdi
343.56M
Markedsverdi kategori
Small-cap
Beskrivelse
Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical trial targeted to hepatocytes that inhibits viral replication and reduces various HBV antigens using novel covalently conjugated N-acetylgalactosamine (GalNAc) delivery technology; and AB-836, an oral capsid inhibitor that suppresses HBV DNA replication. The company's research and development programs include AB-161, an oral HBV RNA destabilizer to destabilize HBV RNA, which leads in the reduction of HBsAg and other viral proteins; AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune response; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has strategic alliance, licensing, and research collaboration agreements with Talon Therapeutics, Inc.; Gritstone Oncology, Inc.; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd.; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Vaccitech plc to evaluate a triple combination of AB-729 for the treatment of chronic HBV infection. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.
Ansatte
85
Investorrelasjoner
-
SEC-innsendelser
Adm. direktør
William H. Collier
Land
USA
By
Warminster
Aksjetype
Common stock
CCC-status
-
Utbyttefrekvens
-
ARRANGEMENTER OG PRESENTASJONER
ArrangementerPresentasjoner
Loading...
FORSTÅ VIRKSOMHETEN
Loading...
NYHETER OM SELSKAPET
Alle nyheterPressemeldinger
WARMINSTER, Pa., Sept. 22, 2022 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop nove...
22. september 2022
WARMINSTER, Pa., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop nove...
6. september 2022
Every investor in Arbutus Biopharma Corporation ( NASDAQ:ABUS ) should be aware of the most powerful shareholder...
6. september 2022
The patent is expected to provide the company with exclusivity for its experimental RNAi therapeutic until at least April 2038.
1. september 2022
WARMINSTER, Pa., Aug. 30, 2022 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel...
30. august 2022
The Cambridge company (Nasdaq: MRNA) alleged in a complaint filed in the U.S. District Court of Massachusetts Friday that Pfizer (NYSE: PFE) and BioNTech's vaccine, Comirnaty, violates three patents M...
26. august 2022
Arbutus Biopharma Corporation ( NASDAQ:ABUS ) shareholders will have a reason to smile today, with the analysts making...
10. august 2022
At this time, I would like to welcome everyone to the Arbutus Biopharma 2022 second quarter financial results and corporate update. Good morning, everyone, and thank you for joining our second quarte...
4. august 2022
Arbutus (ABUS) delivered earnings and revenue surprises of 23.08% and 165.39%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
4. august 2022
Key milestones across our chronic hepatitis B virus (cHBV) and pan-coronavirus programs remain on track Financially strong with a projected cash runway into the second quarter of 2024 Conference Call ...
4. august 2022
Neste side